Literature DB >> 22767650

Intermittent preventive treatment in pregnancy with sulfadoxine-pyrimethamine: the controversy continues.

Julie Gutman.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 22767650      PMCID： PMC4712739          DOI： 10.1093/cid/cis604

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  14 in total

Review 1.  Malaria in pregnancy: pathogenesis and immunity.

Authors:  Stephen J Rogerson; Lars Hviid; Patrick E Duffy; Rose F G Leke; Diane W Taylor
Journal:  Lancet Infect Dis       Date:  2007-02       Impact factor: 25.071

2.  Sulfadoxine-pyrimethamine-based intermittent preventive treatment, bed net use, and antenatal care during pregnancy: demographic trends and impact on the health of newborns in the Kassena Nankana District, northeastern Ghana.

Authors:  Abraham R Oduro; David J Fryauff; Kwadwo A Koram; William O Rogers; Francis Anto; Frank Atuguba; Thomas Anyorigiya; Martin Adjuik; Patrick Ansah; Abraham Hodgson; Francis Nkrumah
Journal:  Am J Trop Med Hyg       Date:  2010-07       Impact factor: 2.345

Review 3.  Drugs for preventing malaria in pregnant women.

Authors:  P Garner; A M Gülmezoglu
Journal:  Cochrane Database Syst Rev       Date:  2006-10-18

Review 4.  Effect of sulfadoxine-pyrimethamine resistance on the efficacy of intermittent preventive therapy for malaria control during pregnancy: a systematic review.

Authors:  Feiko O ter Kuile; Annemieke M van Eijk; Scott J Filler
Journal:  JAMA       Date:  2007-06-20       Impact factor: 56.272

5.  Quantifying the number of pregnancies at risk of malaria in 2007: a demographic study.

Authors:  Stephanie Dellicour; Andrew J Tatem; Carlos A Guerra; Robert W Snow; Feiko O ter Kuile
Journal:  PLoS Med       Date:  2010-01-26       Impact factor: 11.069

6.  Decreasing burden of malaria in pregnancy in Malawian women and its relationship to use of intermittent preventive therapy or bed nets.

Authors:  Gaoqian Feng; Julie A Simpson; Ebbie Chaluluka; Malcolm E Molyneux; Stephen J Rogerson
Journal:  PLoS One       Date:  2010-08-06       Impact factor: 3.240

7.  Competitive facilitation of drug-resistant Plasmodium falciparum malaria parasites in pregnant women who receive preventive treatment.

Authors:  W E Harrington; T K Mutabingwa; A Muehlenbachs; B Sorensen; M C Bolla; M Fried; P E Duffy
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-18       Impact factor: 11.205

8.  Intermittent screening and treatment versus intermittent preventive treatment of malaria in pregnancy: a randomised controlled non-inferiority trial.

Authors:  Harry Tagbor; Jane Bruce; Mitchell Agbo; Brian Greenwood; Daniel Chandramohan
Journal:  PLoS One       Date:  2010-12-28       Impact factor: 3.240

9.  Coverage of malaria protection in pregnant women in sub-Saharan Africa: a synthesis and analysis of national survey data.

Authors:  Anna Maria van Eijk; Jenny Hill; Victor A Alegana; Viola Kirui; Peter W Gething; Feiko O ter Kuile; Robert W Snow
Journal:  Lancet Infect Dis       Date:  2011-01-26       Impact factor: 25.071

10.  A randomized placebo-controlled trial of intermittent preventive treatment in pregnant women in the context of insecticide treated nets delivered through the antenatal clinic.

Authors:  Clara Menéndez; Azucena Bardají; Betuel Sigauque; Cleofé Romagosa; Sergi Sanz; Elisa Serra-Casas; Eusebio Macete; Anna Berenguera; Catarina David; Carlota Dobaño; Denise Naniche; Alfredo Mayor; Jaume Ordi; Inacio Mandomando; John J Aponte; Samuel Mabunda; Pedro L Alonso
Journal:  PLoS One       Date:  2008-04-09       Impact factor: 3.240
View more
  1 in total

1.  Prevalence of intermittent preventive treatment with sulphadoxine-pyrimethamine (IPTp-SP) use during pregnancy and other associated factors in Sekondi-Takoradi, Ghana.

Authors:  Verner N Orish; Onyekachi S Onyeabor; Johnson N Boampong; Richmond Afoakwah; Ekene Nwaefuna; Samuel Acquah; Adekunle O Sanyaolu; Nnaemeka C Iriemenam
Journal:  Afr Health Sci       Date:  2015-12       Impact factor: 0.927
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.